Zai Lab Limited (NASDAQ:ZLAB - Get Free Report) insider Frazor Titus Edmondson III sold 885 shares of Zai Lab stock in a transaction on Tuesday, April 2nd. The shares were sold at an average price of $16.15, for a total value of $14,292.75. Following the completion of the transaction, the insider now owns 22,621 shares of the company's stock, valued at $365,329.15. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.
Zai Lab Trading Down 0.9 %
ZLAB opened at $15.90 on Thursday. The stock has a 50-day moving average price of $19.44 and a 200-day moving average price of $23.68. Zai Lab Limited has a 12-month low of $15.53 and a 12-month high of $40.42.
Zai Lab (NASDAQ:ZLAB - Get Free Report) last issued its earnings results on Tuesday, February 27th. The company reported ($0.98) earnings per share for the quarter, missing the consensus estimate of ($0.87) by ($0.11). The company had revenue of $65.83 million for the quarter, compared to analysts' expectations of $70.41 million. Zai Lab had a negative net margin of 125.46% and a negative return on equity of 37.07%. On average, research analysts anticipate that Zai Lab Limited will post -3.1 earnings per share for the current fiscal year.
Wall Street Analyst Weigh In
Biden out June 13; Kamala won’t replace him?
From Paradigm Press | Ad
On November 16, 2023…
Joe Biden accidentally revealed the name of the candidate…
Who will replace him in the 2024 presidential election.
See who it is HERE.
ZLAB has been the subject of several research analyst reports. Cantor Fitzgerald reissued an "overweight" rating on shares of Zai Lab in a research note on Friday, January 12th. Citigroup dropped their price objective on Zai Lab from $123.00 to $66.00 and set a "buy" rating for the company in a research note on Thursday, February 29th. Finally, Morgan Stanley started coverage on Zai Lab in a research note on Thursday, December 14th. They set an "overweight" rating and a $47.50 price objective for the company. Five investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock has an average rating of "Buy" and an average price target of $64.22.
Check Out Our Latest Research Report on ZLAB
Institutional Investors Weigh In On Zai Lab
Several institutional investors have recently bought and sold shares of the stock. Invesco Ltd. boosted its holdings in Zai Lab by 13.9% during the 1st quarter. Invesco Ltd. now owns 8,258,118 shares of the company's stock valued at $363,192,000 after acquiring an additional 1,006,575 shares during the period. Wellington Management Group LLP raised its position in Zai Lab by 177.6% during the 4th quarter. Wellington Management Group LLP now owns 5,336,457 shares of the company's stock valued at $145,845,000 after purchasing an additional 3,413,829 shares during the last quarter. BlackRock Inc. raised its position in Zai Lab by 1.9% during the 1st quarter. BlackRock Inc. now owns 4,381,747 shares of the company's stock valued at $145,737,000 after purchasing an additional 80,310 shares during the last quarter. Vanguard Group Inc. raised its position in Zai Lab by 54.8% during the 3rd quarter. Vanguard Group Inc. now owns 3,553,080 shares of the company's stock valued at $121,515,000 after purchasing an additional 1,258,009 shares during the last quarter. Finally, Price T Rowe Associates Inc. MD raised its position in Zai Lab by 62.1% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 2,409,373 shares of the company's stock valued at $80,136,000 after purchasing an additional 923,108 shares during the last quarter. 41.65% of the stock is currently owned by hedge funds and other institutional investors.
Zai Lab Company Profile
(
Get Free Report)
Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. Its commercial products include Zejula, an orally administered poly polymerase 1/2 inhibitor; Optune, a cancer therapy that uses electric fields tuned to specific frequencies to kill tumor cells; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; Qinlock to treat gastrointestinal stromal tumors, and VYVGART, a human IgG1 antibody fragment for myesthenia gravis.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
